Form 4: PROCEPT BioRobotics Executive Exercises Options and Sells Shares Valued Over $1.2 Million

Hisham Shiblaq, EVP and Chief Commercial Officer of PROCEPT BioRobotics Corp, exercised stock options for 20,000 shares and simultaneously sold an equivalent number of shares for proceeds exceeding $1.2 million.

Summary

• Hisham Shiblaq, the Executive Vice President and Chief Commercial Officer of PROCEPT BioRobotics Corp (PRCT), engaged in transactions on June 6, 2025.
• Mr. Shiblaq exercised stock options to acquire 20,000 shares of common stock at an exercise price of $5.18 per share.
• Concurrently, he disposed of a total of 20,000 shares of common stock through multiple sales transactions.
• The sales occurred at weighted average prices of $63.7115 (for 12,296 shares), $64.6358 (for 5,904 shares), and $65.3506 (for 1,800 shares).
• The total proceeds from the sale of these 20,000 shares amount to approximately $1,289,000.
• Following these transactions, Mr. Shiblaq directly beneficially owns 63,133 shares of common stock.
• Additionally, he holds 11,578 derivative securities in the form of stock options, which are fully vested and exercisable with an expiration date of December 15, 2030.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there's a sale of shares, it's directly tied to the exercise of options, indicating the executive is monetizing vested equity. It's a common and expected liquidity event for executives, not necessarily a signal of negative company outlook. The executive still retains a significant number of shares.

Positives

• The exercise of stock options indicates that the executive is realizing value from previously granted equity compensation, which is a common and expected part of executive compensation.
• The significant difference between the exercise price ($5.18) and the sale prices (ranging from $63.71 to $65.35) demonstrates substantial paper gains on the vested options.

Negatives

• The sale of 20,000 shares by a key executive, even if tied to option exercise, represents a reduction in their direct equity exposure to the company, which could be interpreted by some investors as a lack of increased conviction.

Risks

• While a routine transaction, significant insider selling, even for liquidity or tax purposes, can sometimes be perceived negatively by the market and potentially lead to short-term downward pressure on the stock price if not understood in context.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This transaction is an individual executive compensation event and does not directly reflect broader industry trends. However, the ability of an executive to realize significant gains from stock options is common in the high-growth medical device and biotechnology sectors, where equity compensation is a key component of remuneration.

Related Party Transactions

• The transaction involves an executive (Hisham Shiblaq) of PROCEPT BioRobotics Corp, making it a related party transaction as defined by SEC regulations for insider reporting.

Stakeholder Impact

• Shareholders: The sale of shares by an executive could be viewed as a neutral to slightly negative signal, but it's a common practice for executives to realize gains from vested options. The executive still holds a substantial number of shares.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

Keywords

PROCEPT BioRobotics, PRCT, SEC Form 4, Insider Trading, Stock Options, Executive Compensation, Share Sale, Hisham Shiblaq, Biotechnology, Medical Devices